Literature DB >> 19768806

Healthcare expenditures for privately insured people with cystic fibrosis.

Lijing Ouyang1, Scott D Grosse, Djesika D Amendah, Michael S Schechter.   

Abstract

With improved survival and new therapies for people with cystic fibrosis (CF), updated information on medical care expenditures for those individuals is needed. We estimated medical care expenditures, including both insurance reimbursements and patient out-of-pocket expenses, for privately insured people with CF and investigated how those expenditures varied with certain complications of CF. From a private insurance claims database of people covered by health plans associated with large corporate employers, we identified people with CF who were currently receiving medical care for the disorder and characterized their medical expenditures during the period 2004-2006. We selected a matching group of people who did not have CF based on age, sex, and geographic area, and calculated incremental expenditures associated with CF. We also examined the effect of age and certain complications of CF on these expenditures. The annual medical care expenditure for a person with actively managed CF averaged $48,098 in 2006 dollars, which was 22 times higher than for a person without CF. This ratio is high relative to other chronic disorders. Outpatient prescription medications made up the largest component of total expenditures for people with CF (39%). Those who were recorded in claims data as having a liver or lung transplant, malnutrition, diabetes, or a chronic Pseudomonas aeruginosa pulmonary infection incurred much higher expenditures than people without these conditions. People with CF will incur high medical expenditures throughout their lifespan. These findings will assist in the development of economic evaluations of future CF screening and management initiatives.

Entities:  

Mesh:

Year:  2009        PMID: 19768806     DOI: 10.1002/ppul.21090

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  22 in total

1.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

2.  The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.

Authors:  Simon Frey; Tom Stargardt; Udo Schneider; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2019-08       Impact factor: 4.981

3.  Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.

Authors:  Abaigeal D Jackson; Andrew L Jackson; Godfrey Fletcher; Gerardine Doyle; Mary Harrington; Shijun Zhou; Fiona Cullinane; Charles Gallagher; Edward McKone
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

4.  Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

Authors:  D R Vandevanter; A Yegin; W J Morgan; S J Millar; D J Pasta; M W Konstan
Journal:  J Cyst Fibros       Date:  2011-07-30       Impact factor: 5.482

5.  Inpatient healthcare trends among adult cystic fibrosis patients in the U.S.

Authors:  Benjamin T Kopp; Wei Wang; Deena J Chisolm; Kelly J Kelleher; Karen S McCoy
Journal:  Pediatr Pulmonol       Date:  2011-09-07

6.  Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Authors:  Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

7.  Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.

Authors:  Donald R VanDevanter; Mary A O'Riordan; Jeffrey L Blumer; Michael W Konstan
Journal:  Respir Res       Date:  2010-10-06

8.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

9.  Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data.

Authors:  Yuanyuan Gu; Sonia García-Pérez; John Massie; Kees van Gool
Journal:  Eur J Health Econ       Date:  2014-08-09

10.  Increased Mortality in Adult Cystic Fibrosis Patients with Medicaid Insurance Awaiting Lung Transplantation.

Authors:  Katelyn Krivchenia; Dmitry Tumin; Joseph D Tobias; Don Hayes
Journal:  Lung       Date:  2016-08-10       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.